Phase 3 trials for a COVID-19 vaccine developed by the Chinese laboratory Sinopharm began this Wednesday in Lima.
Footage shows the outside of the Clinical Studies Center at the Universidad Peruana Cayetano Heredia (UPCH), where part of the trials are being conducted. The location being guarded by security personnel amid the trials.
«It is a group of twenty people with whom we are going through the whole process: Informed consent, medical evaluation, laboratory evaluation and the vaccine. Then there is a period where they are going to rest to evaluate them and that there is no contingency,» said Dr. German Malaga, head researcher of the vaccine at the UPCH.
According to local media, 3,000 people have registered to be part of the clinical trials of the vaccine that will be administered by the UPCH.
Peru has been one of the countries most affected by the coronavirus pandemic with 691,575 infections since the beginning of the outbreak and 29,976 deaths related to the disease, according to data collected by Johns Hopkins University.